An experimental form of immunotherapy could identify and eliminate cancer-driving blood cells harboring a specific mutation while sparing most healthy…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
Eli Lilly’s AJ1-11095, an experimental JAK2 inhibitor recently licensed from Ajax Therapeutics, may be safe and effective at…
An elderly woman with primary myelofibrosis experienced disease worsening despite being on treatment with hydroxyurea and was later found…
Eli Lilly is acquiring Ajax Therapeutics to advance AJ1-11095, an experimental next-generation JAK2 inhibitor designed to deliver deeper,…